Appendix 4G and Corporate Governance Statement
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Dividend/Distribution – CUV
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Appendix 4E & Annual Report
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Notification regarding unquoted securities
CLINUVEL today released a notification regarding unquoted securities.
Read More
Two grounds of Appeal upheld by NICE Panel
In an announcement released today, CLINUVEL provided an updated on the outcome...
Read More
Notification of cessation of securities
CLINUVEL today released a notification regarding cessation of securities.
Read More
Change of Director’s Interest Notice
CLINUVEL today released a notification regarding a change of Director’s interest.
Read More
CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...
Read More
Expansion of CLINUVEL’s global porphyria programs
CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...
Read More
Investor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read More
First stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read More
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More
Relief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More